Like lumasiran, nedosiran (DCR-PHXC) developed by Dicerna pharmaceuticals, targets lactate dehydrogenase A (LDHA) mRNA in the treatment of primary hyperoxaluria (PH) types 1, 2, and 3 [30,35]. The gene discussed is LDHA; the disease is primary hyperoxaluria.